Business Context and Reporting Period
MEDICINOVA INC filed this Form 8-K on March 24, 2010, to disclose a Japanese financial report ("Kessan Tanshin") filed with the Osaka Securities Exchange. The report covers the fiscal year ended December 31, 2009, and provides supplemental financial forecasts for the six months and full year ending December 31, 2010.
Key Financial Metrics and Forecasts
The filing provides forward-looking estimates for 2010 rather than historical results for the current period. Key forecasted metrics include:
- Revenues: $0 (No revenue expected for the interim or full year).
- Operating Loss (Interim 6 months): $(11,360,000).
- Net Loss (Interim 6 months): $(11,257,000).
- Operating Loss (Full Year): $(17,919,000).
- Net Loss (Full Year): $(17,702,000).
- Expected Loss Per Share (Full Year): $1.46 (Basic and Diluted).
- Anticipated Cash Burn (Full Year): Less than $16.0 million.
The filing does not provide specific historical revenue, profit, or cash flow figures for the year ended December 31, 2009, stating only that the Tanshin is substantially the same as the Form 10-K filed on the same date.
Material Changes and Prior Period Comparison
The filing does not contain specific numerical comparisons to the prior comparable period. It references the Form 10-K for the year ended December 31, 2009, for historical data. The primary disclosure is the inclusion of the 2010 financial forecast and supplementary financial statements denominated in Japanese yen (translated at 92.10 JPY/USD).
Guidance, Outlook, and Risks
Management provided a financial forecast for 2010 based on current assumptions, noting that independent auditors have not compiled or reviewed these estimates. The outlook is heavily qualified by significant risks, including:
- Clinical Trial Uncertainty: Risks regarding the results, timing, and cost of clinical trials for product candidates.
- Regulatory Approval: Uncertainty in obtaining or maintaining regulatory approval.
- Third-Party Reliance: Risks associated with third parties conducting clinical trials and manufacturing.
- Strategic Integration: Challenges in integrating the Avigen, Inc. acquisition and combining ibudilast development programs.
- Liquidity and Capital: The ability to raise sufficient capital when needed and the impact of credit market conditions on the investment portfolio.
Investors are cautioned that actual results may differ materially from these estimates.
Investor Verification Checklist
- Verify the historical financial results for the year ended December 31, 2009, in the Form 10-K filed on March 24, 2010.
- Confirm the company's current cash position and runway against the anticipated cash burn of less than $16.0 million for 2010.
- Review the status of clinical trials for ibudilast and other product candidates to assess the validity of the zero-revenue forecast.
- Monitor progress on the integration of the Avigen, Inc. acquisition and potential strategic collaborations.
- Assess the impact of currency exchange rate fluctuations on the company's financials, given the Japanese yen disclosures.